WO2005009480A3 - Implants containing codrugs - Google Patents

Implants containing codrugs Download PDF

Info

Publication number
WO2005009480A3
WO2005009480A3 PCT/US2004/018455 US2004018455W WO2005009480A3 WO 2005009480 A3 WO2005009480 A3 WO 2005009480A3 US 2004018455 W US2004018455 W US 2004018455W WO 2005009480 A3 WO2005009480 A3 WO 2005009480A3
Authority
WO
WIPO (PCT)
Prior art keywords
moiety
constituent
codrug
biologically active
moieties
Prior art date
Application number
PCT/US2004/018455
Other languages
French (fr)
Other versions
WO2005009480A2 (en
Inventor
Paul Ashton
Grazyna Cynkowska
Tadeusz Cynkowski
Thomas J Smith
Original Assignee
Control Delivery Sys Inc
Paul Ashton
Grazyna Cynkowska
Tadeusz Cynkowski
Thomas J Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Sys Inc, Paul Ashton, Grazyna Cynkowska, Tadeusz Cynkowski, Thomas J Smith filed Critical Control Delivery Sys Inc
Publication of WO2005009480A2 publication Critical patent/WO2005009480A2/en
Publication of WO2005009480A3 publication Critical patent/WO2005009480A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Genitourinary system disorders are treated with therapeutic agents, and optionally further with radiation treatments. One aspect of the invention provides a drug delivery device comprising a codrug or a pharmaceutically acceptable salt or prodrug thereof, for administration of at least one biologically active moiety, which codrug comprises: a) at least two constituent moieties, each moiety being a residue of a biologically active compound or a product thereof, including a first constituent moiety and a second constituent moiety; and b) a linkage covalently linking said at least two constituent moieties to form said codrug, said linkage is cleaved under physiological conditions to regenerate said constituent moieties; wherein the device is dimensioned to position two radiation seeds a predetermined distance apart. Another aspect of the invention provides a drug delivery device comprising a codrug or a pharmaceutically acceptable salt or prodrug thereof, for administration of at least one biologically active moiety, which codrug comprises: a) at least two constituent moieties, each moiety being a residue of a biologically active compound or a product thereof, including a first constituent moiety and a second constituent moiety; and b) a linkage covalently linking said at least two constituent moieties to form said codrug, said linkage is cleaved under physiological conditions to regenerate said constituent moieties.
PCT/US2004/018455 2003-06-11 2004-06-09 Implants containing codrugs WO2005009480A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47752603P 2003-06-11 2003-06-11
US60/477,526 2003-06-11
US47902303P 2003-06-16 2003-06-16
US60/479,023 2003-06-16

Publications (2)

Publication Number Publication Date
WO2005009480A2 WO2005009480A2 (en) 2005-02-03
WO2005009480A3 true WO2005009480A3 (en) 2005-07-14

Family

ID=34107601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018455 WO2005009480A2 (en) 2003-06-11 2004-06-09 Implants containing codrugs

Country Status (1)

Country Link
WO (1) WO2005009480A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294077A1 (en) * 2008-06-10 2011-03-16 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9532959B2 (en) * 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
CN105797144B (en) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 Purposes of the composition containing ulinastatin in preparation treatment prostatitis drug
US10508755B2 (en) 2017-07-21 2019-12-17 International Business Machines Corporation Fluid delivery device with hydrophobic surface
EP3996764A4 (en) * 2019-07-10 2023-11-01 Ripple Therapeutics Corporation Surface coatings and implantable devices comprising dimeric steroid prodrugs, and uses thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872130A (en) * 1959-06-22 1961-07-05 Christian Jean Marie Warolin Improvements in and relating to a process for preparing acetylsalicyclic acid anhydride
GB1013235A (en) * 1963-01-17 1965-12-15 Yoshitomi Pharmaceutical Method of preparing polyhydric alcohol esters of acetylsalicylic acid
WO1991009831A1 (en) * 1989-12-26 1991-07-11 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
FR2693373A1 (en) * 1992-07-09 1994-01-14 Univ Toulouse A product capable of releasing an oxazolidinone, in particular chlorzoxazone, and, if appropriate, an acetamidophenol, in particular paracetamol, into the physiological medium, manufacturing processes.
WO1996015809A2 (en) * 1994-11-22 1996-05-30 Laboratori Alchemia S.R.L. Process for the preparation of a pharmacologically active chemical combination
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
WO2002087586A1 (en) * 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
WO2002089915A1 (en) * 2001-05-07 2002-11-14 Xoft Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
WO2002089899A1 (en) * 2001-05-07 2002-11-14 Xoft Microtube, Inc. Combination ionizing radiation and radiosensitizer or immunomodulator delivery devices and methods for inhibiting hyperplasia
US6524232B1 (en) * 2000-12-22 2003-02-25 Advanced Cardiovascular Systems, Inc. Method for radioactive stent delivery
WO2003024455A2 (en) * 2001-09-17 2003-03-27 Control Delivery Systems, Inc. Stent coated with a sustained-release drug delivery and method for use thereof
WO2003043657A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
WO2003049804A2 (en) * 2001-12-10 2003-06-19 Control Delivery Systems Inc. Treatment of genitourinary tract disorders
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
WO2003090710A1 (en) * 2002-04-23 2003-11-06 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
WO2004064839A1 (en) * 2003-01-21 2004-08-05 Control Delivery Systems, Inc. Salts of codrugs of an opioid together with a second active moiety and uses thereto

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872130A (en) * 1959-06-22 1961-07-05 Christian Jean Marie Warolin Improvements in and relating to a process for preparing acetylsalicyclic acid anhydride
GB1013235A (en) * 1963-01-17 1965-12-15 Yoshitomi Pharmaceutical Method of preparing polyhydric alcohol esters of acetylsalicylic acid
WO1991009831A1 (en) * 1989-12-26 1991-07-11 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
FR2693373A1 (en) * 1992-07-09 1994-01-14 Univ Toulouse A product capable of releasing an oxazolidinone, in particular chlorzoxazone, and, if appropriate, an acetamidophenol, in particular paracetamol, into the physiological medium, manufacturing processes.
WO1996015809A2 (en) * 1994-11-22 1996-05-30 Laboratori Alchemia S.R.L. Process for the preparation of a pharmacologically active chemical combination
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
US6524232B1 (en) * 2000-12-22 2003-02-25 Advanced Cardiovascular Systems, Inc. Method for radioactive stent delivery
WO2002087586A1 (en) * 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
WO2002089899A1 (en) * 2001-05-07 2002-11-14 Xoft Microtube, Inc. Combination ionizing radiation and radiosensitizer or immunomodulator delivery devices and methods for inhibiting hyperplasia
WO2002089915A1 (en) * 2001-05-07 2002-11-14 Xoft Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
WO2003024455A2 (en) * 2001-09-17 2003-03-27 Control Delivery Systems, Inc. Stent coated with a sustained-release drug delivery and method for use thereof
WO2003043657A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
WO2003049804A2 (en) * 2001-12-10 2003-06-19 Control Delivery Systems Inc. Treatment of genitourinary tract disorders
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US20030203030A1 (en) * 2002-01-18 2003-10-30 Control Delivery Systems, Inc. Polymeric gel delivery system for pharmaceuticals
WO2003090710A1 (en) * 2002-04-23 2003-11-06 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
WO2004064839A1 (en) * 2003-01-21 2004-08-05 Control Delivery Systems, Inc. Salts of codrugs of an opioid together with a second active moiety and uses thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALSAMINI C ET AL: "SALICILOILDERIVATI DEL 4-AMMINOFENOLO", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 40, no. 10, 1985, pages 770 - 776, XP002011234, ISSN: 0014-827X *
CALVI E ET AL: "SINTESI E STUDIO FARMACOLOGICO DI NUOVI ESTERI DEL NAPROXEN CON DERIVATI DELL'N-OSSIETILPIPERAZINA", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 40, no. 5, 1985, pages 334 - 346, XP002011233, ISSN: 0014-827X *

Also Published As

Publication number Publication date
WO2005009480A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2001019406A3 (en) Amphiphilic prodrugs
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
EP0740650A4 (en) Codrugs as a method of controlled drug delivery
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
WO2007079082A3 (en) Gastric release pulse system for drug delivery
CN102516417A (en) Cyclodextrin-based polymers for therapeutics delivery
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2001062300A3 (en) Caspase activated prodrugs therapy
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
MXPA02011891A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds.
MX2007015480A (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption.
TW200500067A (en) Salts of codrugs and uses related thereto
CA2468649A1 (en) Adenosine a2a receptor antagonists
HK1073252A1 (en) Use of antiseptics in the manufacture of a pharmaceutical preparation for the prevention or treatment of inflammations in the interior of the human body
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
MXPA05013392A (en) Pharmaceutical compositions comprising atorvastatin manufactured without granulation.
PT1212312E (en) NEW FLAVONES DERIVATIVES XANTONAS AND CUMARINAS
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
BR0013793A (en) Prophylactic and therapeutic drugs for ophthalmic diseases
WO2001032631A3 (en) Heterocyclic cytotoxic agents
WO2005009480A3 (en) Implants containing codrugs
EP1431286A3 (en) Prodigiosin derivatives for treating cancer or viral diseases
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase